Health care stocks have been on a run lately, leading the S&P 500’s 11 sectors over the past three months with a gain of ...

Cencora agrees to buy a majority stake in OneOncology for about $5 billion, pauses buybacks, and reiterates fiscal 2026 sales ...

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is initiating a Phase 2 study ...

Recent Performance Puts Planet Labs PBC in Focus Planet Labs PBC (PL) has quietly turned into a strong momentum story, with the stock up roughly 47% over the past month and nearly 87% in the past 3 ...

As of Friday, December 12, Lantheus Holdings, Inc.’s LNTH share price has surged by 5.44%, which has investors questioning if this is right time to sell.

From a technical perspective, Regeneron (REGN) is looking like an interesting pick, as it just reached a key level of support. REGN recently overtook the 20-day moving average, and this suggests a ...

Apellis Pharmaceuticals, Inc. faces a Sell rating amid revenue stagnation, Syfovre challenges, and uncertain long-term profit ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...

Immix Biopharma is advancing NXC-201, showing 95% complete/near-complete response rates and superior safety. Learn why IMMX ...